<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="39911">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02586818</url>
  </required_header>
  <id_info>
    <org_study_id>INR_CSP_015_0001_RD</org_study_id>
    <nct_id>NCT02586818</nct_id>
  </id_info>
  <brief_title>Clinical Performance of InRhythm PT/INR System in a Professional Use Setting</brief_title>
  <official_title>Clinical Performance of the Investigational InRhythm PT/INR System in a Professional Use Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Accriva Diagnostics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Accriva Diagnostics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate and verify the clinical accuracy of the InRhythm PT/INR
      system; a point-of-care, whole blood PT/INR measurement with a reference plasma based PT/INR
      using a laboratory reference instrument and reagent (Sysmex/Innovin) calibrated to the WHO
      rTF09 reference standard.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be performed at a minimum of three (3) different clinical sites where
      patients' VKA therapy is managed and routine PT/INR monitoring is performed.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstrate substantial equivalence with Roche CoaguChek System</measure>
    <time_frame>4-5 weeks</time_frame>
    <description>95% confidence interval for the INR slope and intercept shall contain 1 and 0 respectively and Lin's concordance correlation coefficient shall be greater than or equal to 0.90.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Demonstrate clinical equivalence with Innovin/Sysmex method</measure>
    <time_frame>4-5 weeks</time_frame>
    <description>Bias at 2.0 and 3.0 INR is 10% or less compared to the Reference INR</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Blood Dyscrasia</condition>
  <arm_group>
    <arm_group_label>Normal</arm_group_label>
    <description>SOC fingerstick and venous blood draw for subject not on anticoagulation medications.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Therapeutic</arm_group_label>
    <description>SOC fingerstick and venous blood draw for subjects who are indicated for and have been on anticoagulation medications for greater than or equal to 3 months. Results from this study will be used solely for research purposes and will not be used for anticoagulation management of study subjects. No patient follow up is required.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SOC fingerstick</intervention_name>
    <description>sample collection</description>
    <arm_group_label>Normal</arm_group_label>
    <arm_group_label>Therapeutic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Venous blood draw</intervention_name>
    <description>sample collection</description>
    <arm_group_label>Normal</arm_group_label>
    <arm_group_label>Therapeutic</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects on stable Vitamin K Antagonist Therapy for equal to or greater than 3 months
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subjects must be &gt; 18 years of age.

          -  The subjects must be willing and competent to sign an informed consent.

          -  The subjects must be able to attend the clinic for one visit to donate one FS blood
             sample and one venous blood draw of approximately 10 cc.

        Additional Inclusion Criteria - Therapeutic Group

          -  The subject must require oral VKA anticoagulant therapy.

          -  The patient must have been anticoagulated for at least three months prior to
             enrollment.

        Exclusion Criteria:

          -  The subject is unable to donate fingerstick and venous blood samples.

          -  The subject has a history of clinically significant bleeding associated with incising
             the finger and/or the venipuncture.

          -  The subject is enrolled in any other study that involves an investigational drug
             and/or device.

        Additional Exclusion Criteria - Normal Group

          -  Subjects receiving any form of anticoagulation drugs such as Aspirin or Clopidogrel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Loralie Yzerman, RN BScN CCRN</last_name>
    <phone>760-443-9243</phone>
    <email>lyzerman@accriva.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>VA Loma Linda Healthcare System</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92357</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tiffany Gunneman</last_name>
      <phone>909-583-6361</phone>
      <email>tiffany.gunneman@va.gov</email>
    </contact>
    <investigator>
      <last_name>Ronald Fernando, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cedron N Williams, CCRP</last_name>
      <phone>410-502-8642</phone>
      <phone_ext>3</phone_ext>
      <email>cwill116@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>William Clarke, PhD DABCC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melissa Ladin, MT</last_name>
      <phone>585-276-3927</phone>
      <email>Melissa_Ladin@URMC.Rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Majed A Refaai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 23, 2015</lastchanged_date>
  <firstreceived_date>October 22, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
